Role of Subthreshold Diode Laser in Cases of Diabetic Macular Edema
DOI:
https://doi.org/10.54112/bcsrj.v7i5.2289Keywords:
Diabetic Macular Edema, Diabetic Retinopathy, Laser Therapy, Visual Acuity, Treatment OutcomeAbstract
Diabetic macular edema is a major cause of visual impairment among patients with diabetic retinopathy. A subthreshold diode laser is a retinal-sparing treatment option that may reduce macular thickness and improve vision without causing visible retinal damage. Objective: To evaluate the anatomical and functional outcomes of subthreshold diode laser in patients with diabetic macular edema. Methods: This prospective interventional study was conducted at the Ophthalmology Department of a tertiary care hospital from July 2025 to December 2025. A total of 70 patients with diabetic macular edema were enrolled through non-probability consecutive sampling. Patients aged 30–75 years with best-corrected visual acuity between 0.2 and 1.0 logMAR and central macular thickness between 300 and 500 µm were included. All patients underwent baseline ophthalmic evaluation, optical coherence tomography assessment, and standardized subthreshold diode laser treatment. Follow-up was performed at 1, 3, and 6 months. The primary outcome was change in central macular thickness at 6 months, while secondary outcomes included change in visual acuity, anatomical response, rescue anti-VEGF requirement, and adverse events. Data were analyzed using SPSS version 26. Results: The mean age of the patients was 55.6 ± 8.9 years, and 40 (57.1%) were male. Mean central macular thickness decreased significantly from 386.4 ± 54.2 µm at baseline to 312.9 ± 38.5 µm at 6 months, with a mean reduction of 73.5 ± 41.6 µm (p<0.001). Mean best-corrected visual acuity improved from 0.53 ± 0.20 logMAR to 0.40 ± 0.17 logMAR (p<0.001), while ETDRS letter score improved from 58.2 ± 10.4 to 64.9 ± 9.2 letters (p<0.001). Complete anatomical response was achieved in 24 (34.3%) eyes and partial response in 35 (50.0%) eyes. Rescue anti-VEGF therapy was required in 8 (11.4%) eyes. No clinically visible laser scar, choroidal neovascularization, subretinal hemorrhage, or treatment-related retinal atrophy was observed. Favorable response was significantly associated with shorter duration of edema, baseline central macular thickness <400 µm, and HbA1c ≤8%. Conclusion: Subthreshold diode laser was associated with significant improvement in visual acuity and central macular thickness in selected patients with diabetic macular edema. The treatment showed a favorable safety profile, with no serious laser-related ocular complications. It may be a useful option for patients with mild to moderate edema, shorter disease duration, and better glycemic control.
Downloads
References
1. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580-91. DOI: https://doi.org/10.1016/j.ophtha.2021.04.027
2. Lim JI, Kim SJ, Bailey ST, Kovach JL, Vemulakonda GA, Ying GS, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2025;132(4):P75-P162. DOI: https://doi.org/10.1016/j.ophtha.2024.12.020
3. Hasan SU, Siddiqui MAR. Nationwide prevalence of type 2 diabetes mellitus and prediabetes in Pakistan: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2024;216:111815. DOI: https://doi.org/10.1016/j.diabres.2024.111815
4. Akhtar S, Ashraf S, Buja A, Khalil IA, Albalawi O, Ahmad F, et al. The prevalence of diabetic retinopathy in type-2 diabetes in Pakistan: a systematic review and meta-analysis. Front Clin Diabetes Healthc. 2026;7:1758759. DOI: https://doi.org/10.3389/fcdhc.2026.1758759
5. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomized, double-masked, phase 3 trials. Lancet. 2022;399(10326):741-55. DOI: https://doi.org/10.1016/S0140-6736(22)00018-6
6. Brown DM, Boyer DS, Do DV, Nguyen QD, Sepah YJ, Yoon YH, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomized, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024;403(10432):1153-63. DOI: https://doi.org/10.1016/S0140-6736(23)02577-1
7. Brown DM, Emanuelli A, Bandello F, Barranco JJE, Figueira J, Souied E, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema. Am J Ophthalmol. 2022;238:157-72. DOI: https://doi.org/10.1016/j.ajo.2022.01.004
8. Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, et al. Diabetic macular edema and diode subthreshold micropulse laser: a randomized double-masked noninferiority clinical trial. Ophthalmology. 2023;130(1):14-27. DOI: https://doi.org/10.1016/j.ophtha.2022.08.012
9. Frizziero L, Calciati A, Torresin T, Midena G, Parrozzani R, Pilotto E, et al. Diabetic macular edema treated with 577-nm subthreshold micropulse laser: a real-life, long-term study. J Pers Med. 2021;11(5):405. DOI: https://doi.org/10.3390/jpm11050405
10. Al-Barki A, Al-Hijji L, High R, Schatz P, Do DV, Nguyen QD, et al. Comparison of short-pulse subthreshold (532 nm) and infrared micropulse (810 nm) macular laser for diabetic macular edema. Sci Rep. 2021;11(1):14. DOI: https://doi.org/10.1038/s41598-020-79699-9
11. Passos RM, Malerbi FK, Rocha M, Maia M, Farah ME, Belfort R Jr. Real-life outcomes of subthreshold laser therapy for diabetic macular edema. Int J Retina Vitreous. 2021;7(1):4. DOI: https://doi.org/10.1186/s40942-020-00268-3
12. Gurung RL, FitzGerald LM, Liu E, McComish BJ, Kaidonis G, Ridge B, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice. Int J Retina Vitreous. 2023;9(1):23. DOI: https://doi.org/10.1186/s40942-023-00453-0
13. Altınel MG, Acikalin B, Alis MG, Demir G, Mutibayraktaroglu KM, Totuk OMG, et al. Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema. Lasers Med Sci. 2021;36(7):1545-53. DOI: https://doi.org/10.1007/s10103-021-03306-0
14. El Matri L, Chebil A, El Matri K, Falfoul Y, Chebbi Z. Subthreshold micropulse laser adjuvant to bevacizumab versus bevacizumab monotherapy in treating diabetic macular edema: one-year follow-up. Ther Adv Ophthalmol. 2021;13:25158414211040890. DOI: https://doi.org/10.1177/25158414211040887
15. Koushan K, Eshtiaghi A, Fung P, Berger AR, Chow DR. Treatment of diabetic macular edema with aflibercept and micropulse laser (DAM Study). Clin Ophthalmol. 2022;16:1109-15. DOI: https://doi.org/10.2147/OPTH.S360869
16. Bonfiglio V, Rejdak R, Nowomiejska K, Zweifel SA, Justus Wiest MR, Romano GL, et al. Efficacy and safety of subthreshold micropulse yellow laser for persistent diabetic macular edema after vitrectomy: a pilot study. Front Pharmacol. 2022;13:832448. DOI: https://doi.org/10.3389/fphar.2022.832448
17. Wijeweera C, Ni J, Petocz P, Preda V, Gnanamanickam S, Jabbour J. Efficacy of anti-VEGF monotherapy versus anti-VEGF therapy with subthreshold micropulse laser (SML) in the management of diabetic macular oedema (DMO): a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2024;262:2733-49. DOI: https://doi.org/10.1007/s00417-024-06405-0
18. Hosoya H, Ueta T, Hirasawa K, Toyama T, Shiraya T. Subthreshold micropulse laser combined with anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2024;262:3073-83. DOI: https://doi.org/10.1007/s00417-024-06460-7
19. Jiang Y, He W, Qi S. Evaluating the efficacy of subthreshold micropulse laser combined with anti-VEGF drugs in the treatment of diabetic macular edema: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:1553311. DOI: https://doi.org/10.3389/fendo.2025.1553311
20. Ma CC, Chen PH, Hsieh YH. Optimizing diabetic macular edema treatment: a meta-analysis of subthreshold micropulse laser and anti-vascular endothelial growth factor combination therapy. J Clin Med. 2024;13(16):4782. DOI: https://doi.org/10.3390/jcm13164782
21. Sabal B, Wylęgała E, Teper S. Impact of subthreshold micropulse laser on the vascular network in diabetic macular edema: an optical coherence tomography angiography study. Biomedicines. 2025;13(5):1194. DOI: https://doi.org/10.3390/biomedicines13051194
22. Mistry H, Maredza M, Campbell C, Lois N; DIAMONDS Study Group. Subthreshold micropulse laser versus standard laser for the treatment of central-involving diabetic macular oedema with central retinal thickness of <400 µm: a cost-effectiveness analysis from the DIAMONDS trial. BMJ Open. 2023;13(10):e067684. DOI: https://doi.org/10.1136/bmjopen-2022-067684
Additional Files
Published
How to Cite
License
Copyright (c) 2026 Ali Zain Ul Abidin, Munib Ur Rehman, Iqra Qureshi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
